M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 45 of 54
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
NCT00415909
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00411632
BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00409968
Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer
NCT00507923
Erlotinib Prevention of Oral Cancer (EPOC)
NCT00402779
Mexican and African American Family Focus Groups on Puberty
NCT00528762
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
NCT00418951
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
NCT00410189
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
NCT00411086
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
NCT00412425
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
NCT00410059
BATTLE Program: Sorafenib in Patients With NSCLC
NCT00411671
Vibration Response Imaging (VRI) in Lung Cancer Patients
NCT00506467
OraTest in Combination With Visual Examination and Visual Examination Alone
NCT00537199
Spectroscopy Versus Standard Care in Cervical Cancer Patients
NCT00529464
Non-Invasive Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy Techniques (MRS) for Assessing Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
NCT00490503
Long-Term Follow Up Study for AMD3100 Patients
NCT00476294
Cellular Therapy With Cord Blood Cells
NCT00427557
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
NCT00392769
Olanzapine in Patients With Advanced Cancer and Weight Loss
NCT00489593
Zoledronate With Atorvastatin in Renal Cell Carcinoma
NCT00490698
Malignant Pleural Effusion With ZD6474
NCT00402896
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
NCT00390793
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
NCT00629200
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
NCT00866749
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
NCT00469014
The Effects of Thalidomide on Symptom Clusters
NCT00379353
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
NCT00381004
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
NCT00526032
LY2275796 in Advanced Cancer
NCT00903708
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
NCT00383994
Nutritional Assessment Intervention to Improve Cancer-Related Fatigue
NCT00507260
RTA 744 Injection in Patients With Leptomeningeal Disease
NCT00512460
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
NCT00506948
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
NCT00413478
Project CASA in Promoting Smoke-Free Indoor Air Policy in Mexican American Households
NCT00850954
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
NCT00364286
Feasibility Study of Collecting Multicenter Chronic GVHD Data
NCT00506233
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
NCT00398983
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
NCT00525031
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
NCT00402766
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
NCT00429403
Pre-Surgical Qigong Therapy for Women With Breast Cancer
NCT00495209
Curbing Tobacco Use in Suburban and Rural Schools
NCT00513097
A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients
NCT00519272
Lenalidomide for Patients With Myelofibrosis (MF)
NCT00352794
Dalteparin in Preventing DVT in Participants With Cancer
NCT00525057
Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery
NCT00505024
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
NCT00349596
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
NCT00360438
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.